PXT3003: Positive topline results from pivotal Phase 3 trial for treatment of CMT1A
(WorldNews France)

Press Release Inside Information Pharnext Announces Positive Topline Results from Pivotal Phase 3 Trial of PXT3003 for Treatment of Charcot-Marie-Tooth Type 1A Disease o Higher dose met primary endpoint, the Overall Neuropathy Limitation Scale (ONLS), with statistical significance (p = 0.008) o Higher dose met secondary endpoint, the 10-meter walk test, with statistical significance (p=0.016) o Safe and well tolerated, no treatment related serious adverse event reported in the higher dose group o Based on these positive results, Pharnext intends to file for market approval in the US and Europe o Conference calls today at 11:30 am EDT / 5:30 pm CET in French and 1:00 pm EDT / 7:00 pm CET in...